Flurbiprofen axetil pharmaceutical composition for relieving fever

A technology of flurbiprofen axetil and composition, which is applied in the field of flurbiprofen axetil pharmaceutical composition, and can solve problems such as the application of flurbiprofen axetil that has not been reported in literature

Inactive Publication Date: 2015-03-25
BEIJING LANDAN PHARMA TECH
View PDF4 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] At present, there is no literature report on

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Flurbiprofen axetil pharmaceutical composition for relieving fever
  • Flurbiprofen axetil pharmaceutical composition for relieving fever
  • Flurbiprofen axetil pharmaceutical composition for relieving fever

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] prescription:

[0023]

[0024] Process:

[0025] (1) Preparation of water phase: add glycerin to water to dissolve, heat to 70°C, and set aside;

[0026] (2) Preparation of oil phase: heating soybean oil to 70°C, adding egg yolk lecithin and flurbiprofen axetil, stirring to dissolve;

[0027] (3) Preparation of colostrum: Add the oil phase of step (2) into the water phase of step (1), at a temperature of 70°C, high-speed shear dispersion, shear speed of 10,000 rpm, and time of 15 minutes, to form colostrum;

[0028] (4) pH value adjustment: quickly cool down the colostrum in step (3) below 30°C, and adjust the pH value to 4.5-6.5 with disodium hydrogen phosphate citric acid buffer solution (the molar ratio of disodium hydrogen phosphate to citric acid is 4:1) ;

[0029] (5) High-pressure homogenization: the colostrum in step (4) is homogenized under high pressure by a microfluidizer for 3 times, the pressure is 800-1200 bar, and the temperature is controlled belo...

Embodiment 2

[0033] prescription:

[0034]

[0035] Process:

[0036] (1) Preparation of water phase: add glycerin to water to dissolve, heat to 70°C, and set aside;

[0037] (2) Preparation of oil phase: heat refined soybean oil to 70°C, add egg yolk lecithin and flurbiprofen axetil, stir to dissolve;

[0038] (3) Preparation of colostrum: Add the oil phase of step (2) into the water phase of step (1), at a temperature of 70°C, high-speed shear dispersion, shear speed of 10,000 rpm, and time of 15 minutes, to form colostrum;

[0039] (4) pH value adjustment: quickly cool down the colostrum in step (3) below 30°C, and adjust the pH value to 4.5-6.5 with disodium hydrogen phosphate citric acid buffer solution (the molar ratio of disodium hydrogen phosphate to citric acid is 4:1) ;

[0040] (5) High-pressure homogenization: the colostrum in step (4) is homogenized under high pressure by a microfluidizer for 3 times, the pressure is 800-1200 bar, and the temperature is controlled below ...

Embodiment 3

[0044] Effects on Rat Fever Induced by Dry Yeast

[0045] Take Wistar rats with normal body temperature, weighing 180-220g, pre-adapt to the environment for 5 days, measure the rectal temperature once a day, and measure the rectal temperature every 1 hour before the experiment, for 3 consecutive times, take the average value as the normal value, for The same rat can be used as a fever model if the temperature difference between two consecutive times does not exceed 0.3°C. 60 qualified rats were randomly divided into 6 groups, 10 in each group. The rats in each group were subcutaneously injected with 20% fresh dry yeast in normal saline suspension at 10ml / kg. After 6 hours, the blank group was given normal saline. Positive Control group gives lysine 0.4g / kg, and experimental group gives respectively flurbiprofen axetil 10mg / kg (embodiment 1 sample), flurbiprofen axetil 20mg / kg (embodiment 1 sample), flurbiprofen axetil Ester 10mg / kg (embodiment 2 sample), flurbiprofen axetil 2...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to an application of a flurbiprofen axetil pharmaceutical composition in preparing antipyretics. The flurbiprofen axetil pharmaceutical composition consists of flurbiprofen axetil, oil, egg yolk lecithin, glycerol, disodium hydrogen phosphate, citric acid and injection water, wherein the concentration of the flurbiprofen axetil is 0.1-10mg/ml, the concentration of the oil is 100mg/ml and the concentration of the egg yolk lecithin is 12mg/ml. The flurbiprofen axetil pharmaceutical composition disclosed by the invention can be used for relieving fever of a rat caused by dried yeast.

Description

technical field [0001] The invention relates to the use of a flurbiprofen axetil pharmaceutical composition for reducing fever. Background technique [0002] Flurbiprofen axetil, its chemical name is: (±) 2-(2-fluoro-4-biphenyl)propanoic acid-1-acetoxyethyl ester [0003] Its structural formula is: [0004] [0005] Molecular formula: C 19 h 19 FO 4 [0006] Molecular weight: 330.36 [0007] Flurbiprofen axetil is insoluble in water and needs to be prepared as a liquid emulsion suitable for intravenous injection. Flurbiprofen axetil fat emulsion injection (trade name Kaifen) is a preparation based on the research and development of the concept of drug delivery system, which uses fat emulsion as a drug carrier and encapsulates flurbiprofen axetil. The injection is less irritating and relieves pain. It acts quickly. This product is a non-steroidal analgesic with lipid microspheres as the drug carrier. After the drug enters the body and distributes to wounds and tum...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/107A61K31/216A61K47/24A61P29/00
Inventor 不公告发明人
Owner BEIJING LANDAN PHARMA TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap